Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders
• Trump announces security deal with Denmark on Greenland